|
Fusion gene ID: 3033 |
FusionGeneSummary for ASRGL1_MYBL2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: ASRGL1_MYBL2 | Fusion gene ID: 3033 | Hgene | Tgene | Gene symbol | ASRGL1 | MYBL2 | Gene ID | 80150 | 4605 |
Gene name | asparaginase like 1 | MYB proto-oncogene like 2 | |
Synonyms | ALP|ALP1|CRASH | B-MYB|BMYB | |
Cytomap | 11q12.3 | 20q13.12 | |
Type of gene | protein-coding | protein-coding | |
Description | isoaspartyl peptidase/L-asparaginaseL-asparaginaseL-asparagine amidohydrolaseasparaginase-like 1 proteinasparaginase-like protein 1beta-aspartyl-peptidaseisoaspartyl dipeptidasetestis secretory sperm-binding protein Li 242mP | myb-related protein Bmyb-like protein 2v-myb avian myeloblastosis viral oncogene homolog-like 2v-myb myeloblastosis viral oncogene homolog-like 2 | |
Modification date | 20180523 | 20180523 | |
UniProtAcc | Q7L266 | P10244 | |
Ensembl transtripts involved in fusion gene | ENST00000415229, ENST00000535727, ENST00000301776, ENST00000528206, | ENST00000396863, ENST00000217026, | |
Fusion gene scores | * DoF score | 4 X 4 X 2=32 | 4 X 5 X 3=60 |
# samples | 5 | 8 | |
** MAII score | log2(5/32*10)=0.643856189774725 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(8/60*10)=0.415037499278844 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
Context | PubMed: ASRGL1 [Title/Abstract] AND MYBL2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ASRGL1 | GO:0033345 | asparagine catabolic process via L-aspartate | 19839645 |
Tgene | MYBL2 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 10770937 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChiTaRS3.1 | AI655904 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - | ||
ChiTaRS3.1 | BF056302 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000415229 | ENST00000396863 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
In-frame | ENST00000415229 | ENST00000217026 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
intron-3CDS | ENST00000535727 | ENST00000396863 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
intron-3CDS | ENST00000535727 | ENST00000217026 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
In-frame | ENST00000301776 | ENST00000396863 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
In-frame | ENST00000301776 | ENST00000217026 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
intron-3CDS | ENST00000528206 | ENST00000396863 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
intron-3CDS | ENST00000528206 | ENST00000217026 | ASRGL1 | chr11 | 62123847 | - | MYBL2 | chr20 | 42341699 | - |
Top |
FusionProtFeatures for ASRGL1_MYBL2 |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ASRGL1 | MYBL2 |
Has both L-asparaginase and beta-aspartyl peptidaseactivity. May be involved in the production of L-aspartate, whichcan act as an excitatory neurotransmitter in some brain regions.Is highly active with L-Asp beta-methyl ester. Besides, hascatalytic activity toward beta-aspartyl dipeptides and theirmethyl esters, including beta-L-Asp-L-Phe, beta-L-Asp-L-Phe methylester (aspartame), beta-L-Asp-L-Ala, beta-L-Asp-L-Leu and beta-L-Asp-L-Lys. Does not have aspartylglucosaminidase activity and isinactive toward GlcNAc-L-Asn. Likewise, has no activity towardglutamine. {ECO:0000269|PubMed:19839645}. | Transcription factor involved in the regulation of cellsurvival, proliferation, and differentiation. Transactivates theexpression of the CLU gene. {ECO:0000269|PubMed:10770937}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ASRGL1_MYBL2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
>In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0aa >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0aa >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0aa >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0aa >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0aa >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0aa >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0aa >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0aa |
* Fusion transcript sequences (only coding sequence (CDS) region). |
>In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0nt |
* Fusion transcript sequences (Full-length transcript). |
>In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000415229_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000396863_chr20_42341699_-_0nt >In-frame_ASRGL1_ENST00000301776_chr11_62123847_-_MYBL2_ENST00000217026_chr20_42341699_-_0nt |
Top |
FusionGenePPI for ASRGL1_MYBL2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ASRGL1_MYBL2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ASRGL1_MYBL2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | ASRGL1 | C0162820 | Dermatitis, Allergic Contact | 1 | CTD_human |